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Abstract  
 
Mutual exclusivity is a widely recognized property of many cancer drivers. Knowledge about 
these relationships can provide important insights into cancer drivers, cancer-driving pathways, 
and cancer subtypes. It can also be used to predict new functional interactions between cancer 
driving genes and uncover novel cancer drivers. Currently, most of mutual exclusivity analyses 
are preformed focusing on a limited set of genes in part due to the computational cost required to 
rigorously compute p-values. To reduce the computing cost and perform less restricted mutual 
exclusivity analysis, we developed an efficient method to estimate p-values while controlling the 
mutation rates of individual patients and genes similar to the permutation test. A comprehensive 
mutual exclusivity analysis allowed us to uncover mutually exclusive pairs, some of which may 
have relatively low mutation rates. These pairs often included likely cancer drivers that have been 
missed in previous analyses. More importantly, our results demonstrated that mutual exclusivity 
can also provide information that goes beyond the interactions between cancer drivers and can, 
for example, elucidate different mutagenic processes in different cancer groups. In particular, 
including frequently mutated, long genes such as TTN in our analysis allowed us to observe 
interesting patterns of APOBEC activity in breast cancer and identify a set of related driver genes 
that are highly predictive of patient survival. In addition, we utilized our mutual exclusivity 
analysis in support of a previously proposed model where APOBEC activity is the underlying 
process that causes TP53 mutations in a subset of breast cancer cases.  
Accessibility: http://www.ncbi.nlm.nih.gov/CBBresearch/Przytycka/index.cgi#wesme 
 
1 INTRODUCTION 
Mutual exclusivity is a frequently observed property in two or more genes having mutations in 
cancer patients [1-8]. Mutually exclusive gene pairs (i.e., gene pairs of which simultaneous 
mutations in the same patients are less frequent than it is expected by chance) are observed within 
many cancer types, while some are common across multiple different cancer types [1].  The 
underlying cause of mutual exclusivity might vary depending on the context. In many cases, 
genes mutated in a mutually exclusive way have been found to be members of the same 
functional pathway. In such a case, the mutual exclusivity of their mutation pattern can be 
explained by the pathway centric view of cancer. Specifically, if two genes belong to the same 
cancer-driving pathway, then a mutation in just one of them might suffice to dysregulate the 
pathway and trigger cancer progression [2, 5, 7, 9-11].  In contrast, in a combined analysis of 
multiple cancer types, mutually exclusive aberrations might represent tissue specific cancer 
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drivers. In fact, the sets of mutually exclusive drivers obtained in Pan-Cancer analysis [12, 13] 
predominantly included the tissue type specific genes that, typically, do not share common 
pathways. Yet, even within the same tissue type, mutual exclusivity between genes from different 
pathways is not unusual [1]. This type of exclusivity can be explained, for example, by synthetic 
lethality where simultaneous mutations in both genes are detrimental for cancer progression [14, 
15]. Another (not necessarily unrelated) possibility is that the mutually exclusive drivers define 
different cancer subtypes within the same tissue type. Finally, mutual exclusivity can also be 
observed between less frequently mutated cancer drivers suggesting more subtle relationships 
between them and their contribution to cancer progression. For example, previous research found 
that even if the exclusivity between ARID1B and KRAS is not significant in any of individual 
cancer types separately, the pair was shown to be mutually exclusive when analyzing all cancer 
types together as statistical power was gained [1].  
Mutual exclusivity can potentially provide important information about cancer, including its 
alternative progression pathways and subtypes.  It can also reveal important relationships between 
genes and pathways. However, most of the analyses of mutual exclusivity so far have been 
focused on limited subsets of genes that were selected based on mutation rate cut-off (typically 
3% or 5% depending on datasets) or restricted by other criteria. One of the factors limiting the 
applications of mutual exclusivity analysis beyond restricted gene sets was the cost of computing 
rigorous p-values for all gene pairs of interest. Statistically, pairwise mutual exclusivity can be 
estimated by a permutation test in which the original mutational profile is permuted by swapping 
random pairs of mutations iteratively while preserving the mutation rates of genes and patients.  
A possibly faster alternative approach is to use a hypergeometric test.  However, the 
hypergeometric test treats all patients equally, ignoring patient specific mutation frequencies, 
which may limit its accuracy.  
To provide a more in-depth understanding of mutual exclusivity in cancer data, we started by 
designing a new and fast heuristic for estimating statistical significance of mutual exclusivity 
relationships. Our method, WeSME (Weighted Sampling based Mutual Exclusivity), estimates p-
values of mutual exclusivity while taking into account mutation frequencies of patients. It closely 
approximates the results of the permutation-based method and does so without using the costly 
permutations of a mutation matrix. Moreover, WeSME can compute p-values for a subset of 
genes independently from the rest of genome unlike the permutation method that requires whole 
genome permutations. By dynamically adjusting sampling depth, WeSME can provide high 
precision p-values without a significant increase in computational cost. Adopting the same 
sampling technique, we also developed a complementary test, WeSCO (Weighted Sampling 
based Co-Occurrence), to estimate the significance of co-occurrence in gene mutations. 
With WeSME at hand, we began to explore the information that a comprehensive mutual 
exclusivity survey can provide. We included all genes with mutations in the analysis without pre-
filtering. In particular, we did not exclude very long genes such as muscle protein Titin (TTN), 
gel forming Mucins, which often emerge as frequently mutated genes in cancer (even after 
correction with their lengths) but are generally assumed to be artifacts [16]. Interestingly, we 
found that some of these genes have many mutual exclusivity partners. In particular, we identified 
TTN as one of the hubs in the mutual exclusivity network in breast cancer and endometrial 
carcinoma. The high number of mutual exclusivity partners of TTN prompted us to hypothesize 
that mutual exclusivity of its mutations could be a reflection of an underlying mutagenic process 
that occurs in a specific subgroup of patients.  
To test this hypothesis, we reasoned that long and frequently mutated genes might harbor a 
recognizable signature of the mutagenic process acting on them. Specifically, it has been recently 
recognized that a subclass of APOBEC cytidine deaminases, which convert cytosine to uracil 
during RNA editing, are a source of mutagenicity in human tumors [16-18]. Several other factors 
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such as Pol ε mutation, patient ages at diagnosis, known mutagenic exposures, or defects in DNA 
maintenance are also associated with characteristic mutation signatures [19]. We found that, in 
the case of breast cancer, the mutation pattern of TTN is consistent with the APOBEC3B activity, 
while in endometrial carcinoma, it is consistent with the Pol ε mutation signature. 
Including TTN gene in our mutual exclusivity analysis allowed us not only to observe interesting 
patterns of APOBEC activity in breast cancer but also to identify a set of driver genes that is 
highly predictive of patient survival. In addition, we showed that our mutual exclusivity analysis 
supports the model where APOBEC activity is the underlying process that causes TP53 mutations 
in highly mutated breast cancer cases. Finally, with our method, we have been able to uncover 
mutually exclusive cancer drivers and novel putative drivers despite their relatively low mutation 
rates in the breast cancer dataset. 
Taken together, our results demonstrated the utility of our fast statistical test for mutual 
exclusivity and showed that the unrestricted analysis of mutual exclusivity enabled by the method 
can provide valuable biological insights. 
2 WeSME (WEIGHTED SAMPLING BASED MUTUAL EXCLUSIVITY)   METHOD 
Both hypergeometric and permutation based methods have been popular choices for estimating 
the significance of mutual exclusivity. The drawback of the permutation-based method is the 
computational cost, thus limiting gene sets to be considered and/or precision.  On the other hand, 
the hypergeometric test does not take into account different mutation frequencies of patients and 
often underestimates the significance of exclusivity. WeSME aims to reduce the computational 
cost of estimating the significance of mutual exclusivity by utilizing weighted samplings instead 
of performing costly permutations of a mutation matrix, while accurately computing p-values by 
including patient mutation frequency information in sampling probability (See the discussion on 
the computational costs in Supplementary Section S-A). 
2.1 General description of WeSME method  
WeSME first computes the mutation frequencies of patients based on the observed distribution 
(Algorithm 1 and Figure 1A). Let G = {g1, g2…gm} and S = {s1, s2 ... sn} be the set of all genes 
and cancer patients, respectively. Let mf(s) be the observed mutation frequency of a patient s. 
Next we obtain the null distribution of the mutation pattern of a gene by performing samplings of 
patients based on the weights (mf(s1), mf(s2) … mf(sn)) (Algorithm 2). Specifically, for a gene g 
in G with m(g) mutated patients, we randomly sample m(g) patients without replacement while 
making sure that the probability of a patient s being sampled is proportional to the observed 
mutation frequency mf(s) (i.e., sampling weighted by mf(s)). Let (Rg1, Rg2, Rg3 …RgW) denote the 
sampling results when W weighted samplings were performed for gene g. Rgl corresponds to the 
random subset of patients for gene g in the l-th weighted sampling and the size of Rgl must be 
m(g) for all l. Note that the samplings depend only on m(g) and W, and therefore two genes g1 
and g2  with m(g1)=m(g2) can reuse the same samplings. We use this fact to further reduce the 
sampling time (see Section 2.2 and Supplementary Section S-A). 
To estimate the p-value of mutual exclusivity of two genes gi and gj in G, we compare the number 
of patients exclusively covered by the two genes and the numbers of such patients from the null 
distribution (Algorithm 3). Formally, for two subsets of patients Si and Sj, let us define 
ExCover(Si, Sj ) to be |XOR(Si, Sj)|. Suppose that S(gi) is the set of patients who have mutations in 
gene gi. Then ExCover(S(gi), S(gj) ) represents the exclusive cover size by either gene gi  or gj. As 
in the permutation-based method, the empirical p-value of mutual exclusivity of gi and gj is given 
as 
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p(gi, gj) = |{l=1…W | ExCover(Ril, Rjl)  > ExCover(S(gi), S(gj) )}|/W 
where (Ri1, Ri2, Ri3 … RiW) and (Rj1, Rj2, Rj3 … RjW) are the random samplings of gi  and gj , 
respectively. We note that the precision of p-values depends on the number of weighted sampling 
pairs W.  In Subsection 2.2, we discuss how we increase W to obtain a better precision without 
increasing the computational time significantly. 
One noteworthy advantage of using WeSME over the permutation method is that except 
Algorithm 1, the analysis can be carried out for a subset of genes independently from the rest of 
genome whereas in the permutation method, the whole genome permutations need to be 
performed to obtain random profiles. 
2.2 WeSME provides a fast and accurate approximation to the permutation based 
method 
In this subsection, we discuss some optimization techniques to further reduce the computational 
costs of WeSME and present the results applied to TCGA BRCA dataset.  
Compact sampling: given the observed mutation frequency vector (mf(s1), mf(s2) … mf(sn)) of 
patients, the weighted sampling of a gene g depends only on the number of mutated patients m(g) 
and the number of samplings W. Utilizing this fact, we ran Algorithm 2 for each different m(g) 
instead of running for each gene. More specifically, let K be {k | m(g) = k for some g}. We 
performed W weighted samplings for each different k in K (denoted as WS(k)).  As discussed in 
Supplementary Section S-A, we found that it reduces the sampling time and storage requirement 
significantly. 
Dynamic depth of precision: Suppose that we run Algorithm 3 for two genes gi, gj. Let ki = m(gi) 
and kj= m(gj) and let (Ri1, Ri2, Ri3 …RiW) and (Rj1, Rj2, Rj3 …RjW) denote the weighted random 
samplings for ki and kj respectively. Then there are at least W(W-1) different ways to create the 
pairs (discarding Ril and Rjl when ki = kj in which case Ril and Rjl  are identical) and compute 
ExCover. For added randomness and optimizing the running time, we started by randomly 
selecting a small number of pairs (W0) and compute ExCover for them initially. For example, we 
start with W0 =1,000 pairs at first and if empirical p-value  < 0.1 (there are less than 100 random 
pairs whose ExCover is bigger than the original ExCover), we increased the number of sampling 
pairs by 10 times to obtain a better precision. The maximum precision we used in this analysis is 
10-6 (i.e., the maximum number of pairs =106  W(W-1)) 
Figure 1. Illustration of WeSME method  
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Analysis of TCGA BRCA somatic mutations: we ran WeSME with the somatic mutation 
profile of 665 TCGA BRCA patients. We considered all genes with at least one mutation without 
pre-filtering and computed the p-values of all gene pairs. Figure 2A shows the comparison of the 
p-value distributions obtained by WesME, permutation test, and hypergeometric test for the gene 
pairs with their p-values  0.25. The p-values of the permutation-based method were computed 
using 1,000 randomly permuted mutation profiles (permuted while preserving the mutation 
frequencies of patients and the mutation rates of genes). We found that the results obtained with 
WeSME approximate the ones with the permutation test very well (relative error rate  0.17, 
Pearson corr. coef.  0.98) while the hypergeometric test, in general, underestimates the mutual 
exclusivity (relative error rate  0.97, Pearson corr. coef.  0.89). We noted that WeSME p-
values tend to be slightly more significant than the p-values based on the permutation test 
especially for the gene pairs with significant p-values (see more discussion in Supplementary 
Section S-C). Still WeSME approximates the permutation test much better than the 
hypergeometric test for the significant gene pairs (for pairs with p-value  0.05, relative error rate 
– 0.30 vs. 3.3, Pearson corr. coef. – 0.89 vs. 0.76). This trend of over-estimation was less 
prominent when we considered all gene pairs in HumanNet1 (Figure 2A inset, the whole spectrum 
of p-values are shown).  
False discovery rate (FDR): in order to control FDR, we obtained the null distribution by 
generating 100 permuted mutational profiles and computing WeSME p-values for all gene pairs 
with the permuted mutations (Figure 1B and Algorithm 4).  Observing that the null distribution of 
p-values showed different patterns depending on the mutation rates of involved genes, we divided 
the genes into two groups based on their mutation rates (highly or rarely mutated), which in turn 
divided all gene pairs into three different bins. The null distribution for each bin was created 
separately using the p-values from the permuted mutation profiles. We then computed the FDR of 
the p-value for the gene pairs in each bin by comparing them with the null distribution for the 
                                                
1 http://www.functionalnet.org/humannet/ 
 
  A.! B.!
Figure 2 (A) Comparison of the p-values computed based on permutation, hyergometric and WeSME tests. Only the 
data for the pairs with their p-values ≤ 0.25 are shown. The p-values for the gene pairs in HumanNet are shown in the 
inset. (B) The plot shows the WeSME p-values (p ≤ 0.25) and their corresponding FDRs. FDRs are computed 
separately depending on the mutation rates of genes. 
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corresponding bin. Figure 2B shows the different FDRs obtained using three bins – (R, R), (R, 
H), and (H, H) for BRCA where R (Rarely mutated) includes all genes with the mutation rate of 
2% or lower, and the remaining genes are in H (Highly mutated). There were no pairs in bin (R, 
R) with p-value  0.25. In Figure 2B, we can observe that the pairs in bin (R, H) have higher 
FDRs (shown in purple) than the pairs in bin (H, H) (shown in cyan) for the same p-values.  
2.3 Mutual exclusivity network in BRCA and UCEC 
Figure 3A shows the network with significant mutually exclusive (ME) edges created with BRCA 
somatic mutation profiles. We included the gene pairs with p value  0.01 for highly mutated 
gene pairs in (H, H) and applied a stricter p-value threshold of 0.001 for pairs in (R, H). The 
corresponding FDR  0.125.  We also computed the ME network with TCGA endometrial 
carcinoma (UCEC) somatic mutation data with a stricter FDR cut-off of 0.0025 (Figure 3B). The 
more stringent FDR cutoff was used because the analysis of UCEC patients resulted in a larger 
number of ME pairs, presumably due to its partition into subtypes with drastically different 
mutational profiles. Additional analysis with TCGA Acute Myeloid Leukemia dataset is included 
in Supplementary Section S-E. 
 
 
Figure 3. ME networks for (A) BRCA (FDR ≤ 0.125) and (B) UCEC (FDR ≤ 0.0025).  The node size of each gene 
represents the mutation rate of the gene for the given cancer type. The widths of edges correspond to their WeSME p-
values (thicker edges for more significant pairs) whereas darker colors of the edges correspond to lower FDRs. The 
networks are created using Cytoscape [20] 
 
The BRCA network (Figure 3A) contains 34 mutually exclusive gene pairs. There were 13 pairs 
where one of the genes in the pair was mutated in 3% or less patients including two pairs where 
the mutation rate was below 2%. These genes would have been filtered out if 3% of mutation rate 
threshold was applied. Interestingly, these pairs include five pairs of well-known drivers: 
(ARID1A, TP53), (MTOR, PIK3CA), (AKT1, PIK3CA), (AKT1, TP53), (CTCF, TP53); four 
pairs where one member is a known cancer driver and its partner is a likely (and previously 
implicated) cancer driver: (TP53, MED23), (PIK3CA, PEG3)[21], (CBFB, TP53) [22] (USP36, 
PIK3CA) [23]; and three pairs where one member is a long gene - Titin (TTN)  or Cytoplasmic 
Dynein 2 Heavy Chain (DYNC2H1) – while its partner is a known cancer driver (TTN, 
ARID1A), (AKT1, TTN), (DYNC2H1, PIK3CA). Previous work suggested that TTN and 
DYNC2H1 are unlikely to be cancer drivers [24].  Yet, TTN has rather a large number of partners 
A. B.!
 7 
in the mutual exclusivity network, suggesting that patients carrying mutations in this gene may 
have some distinguishing properties.  
As for endometrial carcinoma, the previous analysis on TCGA UCEC dataset identified 12 genes 
(PTEN, TP53, PIK3CA, PIK3R1, ARID1A, ARID5B, KRAS, CTCF, CTNNB1, FBXW7, 
PPP2R1A, RPL22) as recurrently mutated in different subtypes [25].  All but ARID5B and 
RPL22 are included in the ME network obtained with FDR cut-off of 0.0025.  RPL22 and TP53 
pair had FDR=0.00256 while the most significant ME partner of ARID5B was CTNNB1, for 
which FDR=0.02. Though overlooked in the TCGA publication, TRRAP 
(transformation/transcription domain-associated protein) is likely to be an important driver. The 
gene encodes a protein that plays a role in transcription and DNA repair. With our very stringent 
FDR cut-off, TRRAP is mutually exclusive with CTNNB1 and PIK3CA. Finally, as in the case of 
BRCA, the TTN gene has four neighbors, all of which are prominent cancer drivers.  
In our subsequent analysis in Section 3, we show that although TTN may not be a cancer driver 
itself, it is likely to be a passenger of a mutagenic process that is specific to a subgroup of patients 
in these two cancer types. 
3 BEYOND MUTUAL EXLUSIVITY OF DRIVERS - DISCOVERING DRIVER 
SIGNATURES FROM MUTUAL EXLUSIVITY PARTNERS OF PASSENGERS   
3.1 APOBEC and POL ε mutational signatures of TTN 
Recent studies identified several genes that are highly mutated but still unlikely to be cancer 
drivers [16]. These genes are often extremely long genes, including the muscle protein Titin 
(TTN), gel forming mucins (MUC), and ryanodine receptors (RYR1). Those genes were mostly 
excluded from candidate cancer driver lists in subsequent analyses. However, some of the 
apparent false-positive findings may not be simply caused by their lengths since the methods for 
identifying significantly mutated genes typically account for gene length information.  
TTN is one of the genes identified as the ones that are not likely a cancer driver despite its high 
mutation rate but the prominent position of TTN in both BRCA and UCEC mutual exclusivity 
network strongly suggests that the mutagenesis of TTN may provide valuable information about 
patient subgroups.  That is, even if TTN is not a cancer driver, the gene may be a passenger that is 
mutated in a specific group of patients and be a “witness” of a mutagenic process occurring in the 
subgroup.  
To confirm the hypothesis that TTN is a witness of a particular mutational process, we analyzed 
the mutational spectrum of this gene for both cancer types (BRCA and UCEC), and compared it 
to the signatures of mutational processes in human cancer [19]. We found that the mutational 
signature of TTN in BRCA dataset was consistent with the APOBEC signature. It showed a 
significant bias towards C>T and C>G mutations – 67 and 44 mutations respectively (38% and 
25% of 175 mutations in total and 50% and 33% of 132 C cite mutations). In addition, most of 
these mutations are in the context where C is preceded by A or T (71%).  
In UCEC dataset, on the other hand, TTN has a different mutation signature, which is consistent 
with Pol ε mutations. TTN showed a strong preference for C>A and C>T mutations, having 231 
and 347 mutations respectively, which represents 30% and 46% of 761 mutations in total and 
40% and 59% of C cite mutations.  Moreover, 123 of C>A mutations (53%) are TCT>TAT and 
116 mutations of C>T mutations (33%) are TCG>TTG, strongly demonstrating that TTN 
mutations in UCEC is associated with Pol ε mutation signature. 
3.2 Mutual exclusivity patterns of TTN and TP53 indicate a group of genes predictive of 
patient survival and suggest a role of APOBEC3 activity in TP53 mutations.  
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ME network and survival analysis: An interesting property of mutational landscape of breast 
cancer is that frequently mutated genes such as TP53, PIK3CA, TTN and GATA3 in breast 
cancer do not have a strong discriminative power of patient survival (only TP53 mutations are 
weakly discriminative, p-value = 0.08). We therefore asked the question whether the mutual 
exclusivity network could suggest a set of genes with a better discriminative power.  
Previous studies have suggested that APOBEC3B activity correlates with unfavorable prognosis 
in breast cancer. For example, it has been shown that APOBEC3B gene expression correlates 
with the Genomic Grade Index (GGI) score and that high APOBEC3B gene expression was 
associated with recurrence after treatment [26]. According to a separate study, APOBEC3B was 
associated with poor survival in ER+ breast cancer patients [27]. Building on our observation that 
TTN mutations are largely due to APOBEC3B activity (as discussed in the previous section), we 
hypothesized that putative cancer drivers exclusive with TTN mutations would be characterized 
by better prognosis. This was indeed confirmed in our survival analysis. We found that four genes 
that are exclusive with TTN  (MAPK3K1, NCOA3, AKT1, ARID1A) were a good predictor of 
survival jointly and also predict disease free survival after treatment very well (Figure 4B). 
Interestingly, TTN and TP53 share the discriminative gene set as their direct ME neighbors in the 
BRCA ME network (Figure 3A). On the other hand, adding other putative drivers exclusive with 
TP53 but not with TTN (FOX1A, MED23, MAP2K4)2 reduced the discriminatory power of the 
gene set.   
Role of APOBEC3B activity in TP53 mutations: The similarity of exclusivity patterns of TTN 
and TP53 is consistent with the recently discovered relationship between APOBEC enzymatic 
activity and TP53 mutations [18]. In their research, Burns et al. hypothesized that APOBEC3B-
catalysed deamination provides a chronic source of DNA damage that could cause TP53 
mutations.  
To support the model proposed by Burns et al., we need to test if it is possible that the mutations 
of both genes in BRCA depend on APOBEC activity but are independent of each other after 
controlling for their dependency on APOBEC. That is, under this model, we expect TTN and 
TP53 to co-occur but the significance of co-occurrence to disappear after correcting with 
mutation frequencies of patients. To test if this is the case, we developed WeSCO (Weighted 
Sampling based Co-Occurrence) by adopting the same sampling technique as WeSME for 
estimating the significance of co-occurrence of mutations corrected with patient mutation 
frequency. Indeed, we did not find a significant co-occurrence (Figure 4C, p-value = 0.29) of 
TTN and TP53 when applying WeSCO test while the co-occurrence was highly significant 
without the correction (p-value = 0.0002, hypergeometric test).  
Although it is currently not known how APOBEC activity leads to TP53 mutations, we 
conjecture that immune response might be the precursor step leading, via APOBEC activity, to 
TP53 mutation for some cancer patients. It has been demonstrated that the AID/APOBEC family 
plays important roles in adaptive and innate immunity [28] and APOBEC up-regulation is 
correlated with HPV-positive status, which implicates an HPV-mediated mechanism of 
APOBEC3B up-regulation for these cancer types [29]. In particular, the authors provided 
evidence that APOBEC activity is responsible for the generation of helical domain hot spot 
mutations in PIK3CA across multiple cancers. The key role of APOBEC family in natural and 
adaptive immunity strongly suggests that APOBEC up-regulation may be also related to immune 
response in non-HPV mediated cases and our results support a similar mechanism for TP53 
mutations in some breast cancer cases (but not all cases as discussed below).  
Underlying causes of TP53 mutations may be heterogeneous: We observed that the subgroup 
of patients with TP53 mutations but no TTN mutations had significantly lower mutation 
                                                
2 CTCF was not included because it shows a slight tendency of exclusivity with TTN, p-value < 0.15 
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frequencies compared to the subgroup of patients with TTN mutations (Figure 4C; p-value = 
0.025). This suggests that the TP53 only group also contains patients whose TP53 mutations are 
not due to APOBEC activity as otherwise we would not expect to see a difference in mutation 
frequencies between the TP53 only and the TTN patient groups.  The difference of mutation 
frequencies in the group suggests that underlying causes of TP53 mutations in breast cancer are 
heterogeneous. 
Interestingly, TP53 and TTN mutations are mutually exclusive in the analysis of endometrial 
carcinoma data where TTN mutations show Pol ε mutation signature (Figure 3B). This 
observation suggests that the mutations in TP53 are generally not caused by the mutagenic 
process related to Pol ε mutations. 
In summary, our results are consistent with the previously proposed model in which APOBEC3B 
can be a source of mutations in TP53 for highly mutated cancer cases, however reject the model 
in which this is true across all breast cancer patients with TP53 mutations.  
4 CONCLUSIONS  
We performed a whole genome scale analysis of mutual exclusivity of genes with mutations in 
breast cancer and endometrial carcinoma. For this purpose, we first developed WeSME - a new, 
fast method to estimate statistical significance of mutual exclusivity. Similar to the permutation 
based method, WeSME controls mutation frequencies of patients and mutation rates of genes in 
the null model, but can be performed quickly with a nearly arbitrary level of precision. The p-
values estimated by WeSME closely matched the p-values obtained with the permutation-based 
method. In addition, our proposed method to control FDR takes into account the differences of p-
value distributions from gene pairs with different mutation rates. 
The development of WeSME allowed us to perform a large-scale mutual exclusivity analysis 
without restricting it to highly mutated genes or genes known a priori to be cancer drivers.  The 
approach led us to uncover mutually exclusive cancer drivers, some of which have relatively low 
mutation rates. In addition, our mutual exclusivity analysis allowed us to pinpoint differences 
between mutagenic processes in different cancer groups. In particular, the inclusion of TTN (a 
very long and frequently mutated gene) not only allowed us to observe the patterns of APOBEC 
activity in breast cancer and Pol ε mutation signature in endometrial carcinoma but also help 
identify a set of driver genes that is highly predictive of patient survival. TTN was considered to 
be an artifact and typically filtered out in cancer analyses. 
Taken together, we developed a tool enabling a fast genome-wide analysis of mutual exclusivity 
of mutations in cancer and used it to demonstrate that the genome-wide mutual exclusivity 
analysis can provide information beyond relationships between cancer drivers.   
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Figure 4. Mutual exclusivity of TTN and TP53 defines a group of related genes that are predictive of survival. A) Genes mutually 
exclusive with TP53 (purple) and TTN (blue) with FDR cutoff of 0.125 (except of FOXA1 for which p-value is 0.00365 and FDR = 
0.3) with their context of functional interactions based on [31]. The interactions between FOXA1 and GATA3 are based on [32], and 
the relationships between EP300 and SWI/SNF and between CTCF and SWI/SNF are from [33, 34] and [35], respectively. B) Cancer 
driver genes AKT1, NCOA3, ARID1A, and MAP3K1 that mutually exclusive with both TTN and TP53 provide a better survival 
prognosis. C) Comparison of mutation frequencies for patients with TTN and TP53 mutations. The numbers in the Venn diagram 
represent the number of patients and the average mutation frequencies of the corresponding groups are shown above the diagrams.  
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A COMPARISON OF WESME AND PERMUTATION METHOD 
The main difference between WeSME and the traditional permutation method lies in how random 
mutation profiles are generated. Once random profiles are generated, the computation of 
empirical p-values can be performed in a similar way for both methods. To compare their 
computational cost, we measured the total time and storage required to generate random profiles 
using the two methods for the somatic mutation profile of 665 TCGA BRCA patients (Table S1). 
We used all genes with at least one mutation without pre-filtering. In the permutation method, a 
mutation matrix is shuffled while the mutation frequencies of cancer patients and the mutation 
rates of genes are preserved*. For the purpose of comparison, we show the cost when WeSME 
samplings were run for all genes (the second column in Table S1) but note that we only need to 
generate random profiles for each different k (the number of mutated patients) instead of 
generating them for all genes (see Section 2.2). The last column in Table S1 shows the results for 
compact sampling.  
Table S1: Comparison of the total computation time and storage required for the permutation method 
and WeSME. For WeSME, the data have been measured in two scenarios – i) sampling is performed 
for each gene separately and ii) sampling only for each different number of mutated patients.  
                                                
* To ensure the randomness of the data, we performed swapping of mutations 100*|E| times where |E| is the 
total number of mutations [1] 
† 104 random profiles correspond to the p-value precision depth of 10-4. While the permutation method 
requires generating 10p random instances for an entire mutation profile to obtain the precision of 10-p in p-
values, WeSME can decide the precision depth of p-values independently for different gene pairs. We show 
the time and storage requirement to generate the same 104 random instances using WeSME only for the 
purpose of comparison.  
 
  permutation WeSME  
for all genes 
WeSME 
1 random 
profile  
time (sec) 100.67 2.31 0.018 
file size 
(KB) 
226 226 1.2 
  104  random 
profiles†  
 
total time 
(hour) 
279.6  6.4  0.05 
total file 
size (GB) 
2.26 2.26 0.012 
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Besides the reduced computation time and file sizes, an important advantage of WeSME is that 
the samplings for each gene can be generated separately as needed. For instance, in case we are 
interested in finding out the relationships among a certain subset of genes, random weighted 
samplings can be generated only for the genes of interest quickly whereas the permutation 
method requires performing permutations for the entire genome. This property also allows 
WeSME dynamically to adjust the precision of empirical p-values by generating more random 
profiles for some gene pairs if necessary. In the permutation method, 10P permutated matrices of 
the whole genome should be generated to obtain the precision of 10-P even though such precision 
may not be necessary for most of non-significant gene pairs.  
B SLIGHT TENDENDENCY OF WESME TO OVERESTIMATE P-VALUES FOR 
HIGHLY MUTATED GENES 
We noticed in Figure 2A that WeSME slightly overestimated p-values compared to the 
permutation method especially for highly mutated genes. We conjecture that this is due to the fact 
that weighted samplings were performed for each gene (or for each different k more precisely) 
independently. In the permutation test, permutations are performed genome-wide and there exists 
dependency between genes to keep the mutation frequencies preserved. WeSME uses the 
mutation frequencies of patients as weights for sampling to ensure that each patient is sampled 
with the probability in proportion to its mutation frequency, but the mutation frequency in null 
distribution is not guaranteed.  
To find out how the mutation frequencies differ in the null distributions of two methods, we 
plotted the patient mutation frequencies in the generated null distribution for PIK3CA (y-axis in 
Figure S1 (A)) and for TTN (Figure S2 (A)) along with their observed mutation frequency from 
the original mutational profile (x-axis). PIK3CA is the most highly mutated genes in the dataset 
(237 out of 665 BRCA patients) and TTN is mutated in 110 patients. To obtain the null frequency 
of each patient, we generated 1,000 random mutation profiles using both methods and then 
computed, for each patient, the fraction of instances in which the patient has a mutation in 
PIK3CA (or TTN). The observed mutation frequency of a patient s (x-axis) is obtained by 
computing mf(s) * m(g) with an assumption of independent sampling (i.e., sampling m(g) times 
with probability mf(s) with replacement). In methods, the null frequencies and observed mutation 
frequencies are not linear especially for the highly mutated patients because the random 
samplings or permutations do not allow replacements (therefore the null frequency cannot be 
greater than 1). As we can see in the figure, the patients with higher mutation frequencies tend to 
have higher null frequencies in WeSME than in permutation method. We believe that this is 
because the permutation test ensures the mutation frequency of each patient remains the same  
when generating random profiles and therefore, the extra dependency creates less frequency 
Figure S1.  Comparison of mutation frequencies of each patient in the null distributions generated by WeSME and 
permutation (A) mutations in PIK3CA (B) mutations in TTN (C) mutations in both PIK3CA and TTN 
B.   TTN A.   PIK3CA C.   PIK3CA and TTN 
 3 
variations among patients.  
The ME p-values between PIK3CA and TTN are 0.247 and 0.61 using WeSME and the 
permutation test, respectively. To investigate the underlying cause of the difference, we plotted, 
for each patient, the fraction of instances (out of 1,000 random mutation profiles) in which both 
PIK3CA and TTN have mutations in the patient (Figure S1(C)). Each dot represents a patient 
with its null frequency of co-occurrence in y-axis. While WeSME and permutation methods have 
similar co-occurring frequencies in the patients with low mutation frequencies, the difference is 
more noticeable in the highly mutated patients. This implies that the two genes are more likely to 
co-occur in WeSME null distribution than in the null distribution generated by permutations, 
which in turn translates to more significant p-values in WeSME compared to the permutation 
method. We do not observed similar patterns in less mutated genes and the p-values tend to be 
similar in both methods for those genes. 
C WESCO VALIDATION 
As with WeSME, we compared the p-values of co-occurrence with WeSCO, permuation and 
hypergeometric test and plotted the results in Figure S2. Due to the time required to compute p-
values using permutation and hypergeometric test, we only considered 1% randomly selected 
pairs with WeSCO p-value < 0.25.  As shown in the figure, WeSCO p-values correlates very well 
with the p-values computed with the permutation test whereas the p-values obtained using 
hypergeometric test tends to overestimate co-occurrence. 
Figure S2. Comparison of the p-values computed based on permutation, hyergometric and WeSCO 
tests. Only the data for 1% of random chosen pairs with their p-values ≤ 0.25 are shown. 
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D WESME PSEUDOCODE  
Algorithm 1. Compute the weights of patients  
Input binary mutation matrix M 
Output mutation frequency vector (mf(s1), mf(s2) … mf(sn)) 
1. for each patient si: 
mc(si)  ! the number of genes mutated in si  
2. compute the mutation frequency vector (mf(s1), mf(s2) … mf(sn)) by 
normalizing (mc(s1), mc(s2) … mc(sn)) with the total number of mutations 
Σi mc(si) 
3. return (mf(s1), mf(s2) … mf(sn)) 
Algorithm 2.  Generate weighted sampling  
Input  mutation frequency vector (mf(s1), mf(s2) … mf(sn)) 
k: number of patients to be sampled each time 
W: number of times to be performed sampling 
Output W sets of k random patients WS(k) = (R1, R2, R3 … RW), |Rj| = k 
1. for j = 1… W: 
Rj ! randomly select k patients without replacement so that the 
probability to choose si is mf(si)  
2. return (R1, R2, R3 … RW) 
Algorithm 3.  Compute ME p-value 
Input  g1, g2: gene pair  
 Wo: initial number of sampling pairs 
 Wm: maximum number of sampling pairs 
 pmin:: minimum number of sampling pairs with bigger ExCover 
Output  pv: p-value 
1. S(gi) ! set of patients with gi mutated (i =1, 2) 
2. OriginalCover ! ExCover(S(g1), S(g2) )   
3. ki !  m(gi ), (i =1, 2) 
4. W ! Wo 
5. while W ≤ Wm: 
P ! Randomly selected W pairs of indices = ((l11, l21) … (l1W, l2W)) 
 s.t.  l1j ≠ l2j   for all j and (l1j, l2j) ≠ (l1k, l2k) for any j ≠ k  
pv = 0 
For each pair (l1j, l2j) in P: // compute p-value 
 Ri !  li j-th set in WS(ki), (i =1, 2) 
If ExCover(R1, R2)) ≥ OriginalCover: 
 pv ! pv+1/W    
 if pv ≤ pmin /W:  // increase precision 
  W ! W*10 
6. return pv 
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E TCGA ACUTE MYELOID LEUKEMIA DATASET ANALYSIS 
 
We applied WeSME in 194 TCGA Acute Myeloid Leukemia patients [2] and the gene pairs with 
FDR < 0.15 are shown in Figure S3. We used two bins with 5% mutation rate cutoff.  
 
Algorithm 4.  Compute FDR 
Input  M: binary mutation matrix  
PVS: WeSME p-values for all gene pairs  
 mth: mutation rate threshold for bins 
Output  FDRS: FDRs of the gene pairs 
1. for t in [1..100]:  // compute WeSME p-values with permuted instances  
 Mt ! permute M 
 For each gene pair (gi, gj): 
  PVt (gi, gj) ! compute WeSME p-value based on Mt 
      // use three bins for gene pairs by dividing genes into two groups 
      // can be extended to use more bins if necessary  
2. R ! genes with mutation rate ≤ mth 
3. H ! genes with mutation rate > mth 
4. divide gene pairs into three bins [(R, R), (R, H), (H, H)] 
5. for each bin B in [(R, R), (R, H), (H, H)]:  
PVSB !  PVS for gene pairs in B 
PVSBnull ! empty list 
For t in [1..100]: 
 PVSBnull ! PVSBnull +PVt for gene pairs in B 
For each gene pair (gi, gj) in B: 
 V= rank of PVS(gi, gj) in PVSBnull/|PVSBnull| 
 R = rank of PVS(gi, gj) in PVSB/|PVSB| 
FDRS (gi, gj) = V/R 
6. return FDRS 
7. For each bin B in [(R, R), (R, H), (H, H)]:  
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Figure S3. ME network for TCGA LAML (FDR < 0.15). The node size of each gene represents the mutation rate of 
the gene for LAML. The widths of edges correspond to their WeSME p-values (thicker edges for more significant 
pairs) whereas darker colors of the edges correspond to lower FDRs. The networks are created using Cytoscape [3]  
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